Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALLO 715

Drug Profile

ALLO 715

Alternative Names: ALLO-715; Anti-BCMA AlloCAR T; Anti-BCMA CAR T cell therapy - Allogene; UCARTBCMA

Latest Information Update: 17 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellectis
  • Developer Allogene Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 13 Jan 2020 Allogene Therapeutics and SpringWorks Therapeutics agree to conduct clinical trial of ALLO 715 in combination with nirogacestat for Multiple myeloma
  • 13 Jan 2020 Allogene Therapeutics and SpringWorks Therapeutics plans a clinical trial for Multiple myeloma (Combination therapy, Refractory metastatic disease, Second-line therapy or greater)
  • 07 Dec 2019 Pharmacodynamics data from a preclinical studies in Multiple myeloma presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top